secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-06-16T11:15:40+00:00
Accession:  0001493152-26-028807
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Reports Positive Preliminary Human Data for HCW9302 Phase 1 Trial in Alopecia Areata
--------------------------------------------------------------------------------

- All three patients in second dose cohort (3 µg/kg) showed ≥25% reduction in SALT scores after single dose, indicating clinical response.
- No dose-limiting toxicities, capillary leak, cytokine release syndrome, or increased eosinophil counts reported; only mild injection-site reactions.
- Company projects to establish Recommended Phase 2 Dose by year-end 2026 and is dosing third cohort (8 µg/kg).
- HCW9302 is a first-in-kind IL-2 based fusion immunotherapeutic with strong IL-2Rα bias, potentially best-in-class for autoimmune diseases.
- CEO Hing C. Wong stated results consistent with preclinical studies showing Treg expansion and reduced inflammation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/0001493152-26-028807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-028807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer